Navigation Links
Prophylactic cranial irradiation in small cell lung cancer significantly increases survival
Date:8/16/2007

Prophylactic cranial irradiation after chemotherapy significantly reduces the risk of brain metastasis and doubles one-year survival in small-cell lung cancer (SCLC), according to the results of the multicenter phase III randomized EORTC trial 08993-22993, published in the New England Journal of Medicine today.

Small cell lung cancer (SCLC) is an aggressive tumor that constitutes nearly 15% of all newly diagnosed lung cancers. The majority of patients with SCLC present with extensive disease (ED) at diagnosis, meaning that the cancer has spread to other areas of the body. Without treatment, consisting of chemotherapy, the median survival is two to four months. Despite treatment, in most patients, disease progression will lead to dead within one year. Cancer spreading to the brain is an important cause of death and has a profound negative effect on psychological and physical functioning.

Background

Studies conducted primarily in the 1980 had shown that for patients with limited SCLC and complete response to chemotherapy, prophylactic brain irradiation reduced the risk of brain metastasis and improved survival.

In the EORTC 08993-22993 study, Ben Slotman, MD, PhD, Professor of Radiation Oncology at the VU University medical center in Amsterdam, and his European colleagues from the EORTC Radiation Oncology and Lung Cancer Groups extended the use of prophylactic cranial irradiation (PCI) to patients with extensive SCLC. 286 patients were randomized to either receive prophylactic irradiation or to being observed, following four to six cycles of chemotherapy that induced a response of their SCLC.

Results of the study

One year after being randomized in the trial, only 14.4 % of the patients that received PCI suffered from symptomatic spread of their cancer to the brain, compared with 40.4 % of the patients who did not receive PCI. Moreover, 27.1% of the patients receiving PCI were alive after one year, compared with 13.3% of the patients who were not prophylactically irradiated.

Why this study is important:

Prophylactic cranial irradiation significantly reduces the risk of symptomatic brain metastases and significantly prolongs survival according to Prof Slotman. As this treatment is well tolerated and does not adversely influence quality of life, prophylactic cranial irradiation should now routinely be offered to all SCLC patients with extensive disease whose cancer responds to chemotherapy.

For Roy S Herbst, MD, PhD, Professor of Medicine in the Department of Thoracic/Head and Neck Medical Oncology, University of Texas/Section Chief of Thoracic Medical oncology at the MD Anderson Cancer center in Houston, Texas, the results of this study represented the most important clinical finding for the treatment of patients with lung cancer presented at ASCO 2007 in June this year. I expect prophylactic cranial irradiation will be taken up quickly in the US, as well he commented in an interview during ASCO 2007.

Furthermore, this trial was impressive because it showed that a standard modality, such as radiation therapy, still has the potential to improve survival. In this era of targeted therapies, we cannot forget that standard modalities can still improve disease outcomes. he adds.

Moreover, the trial results give weight to the further research hypothesis that thoracic radiotherapy - using the nowadays advanced radiotherapy techniques - might be beneficial to this pretreated patient group as well - a hypothesis Prof Ben Slotman and colleagues are preparing to test in clinical randomized trial to run in The Netherlands, the UK and possibly more European countries.

The challenge in the future remains how to integrate the current modalities with the newer targeted modalities. This EORTC trial shows once again that in clinical cancer research, pursuing a multidisciplinary research agenda can be crucial for improving patient survival. explains Franoise Meunier, MD, PhD, Director General of the EORTC.


'/>"/>

Contact: Ben J Slotman
bj.slotman@vumc.nl
31-204-440-414
European Organisation for Research and Treatment of Cancer
Source:Eurekalert

Related medicine news :

1. New MRI Technique Measures Intracranial Pressure in Brain Disorder
2. Partial-Breast Irradiation an Unproven Therapy
3. Medulloblastoma Irradiation In Young Children Found To Impair IQ And Reading Skills
4. Risk of Thyroid cancer is increased after Childhood Irradiation of Neck region
5. Research Finds Lesser Rectal Cancer Risks Associated with Prostatic Irradiation
6. Smallpox as Biological Weapons?
7. Is Smallpox Threat Real ?
8. Smallpox Vaccine May Help Fight Cervical Cancer
9. Smallpox Would Spread Rapidly
10. Brain of Cocaine Addicts Smaller In Size
11. Problematic Use of smallpox vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology: